2.1 Required Elements: What Must Be Included

Comprehensive review of all elements required by 21 CFR 50.25(a) and ICH E6(R3), with rationale for each requirement.

2.2 Additional Elements and Study-Specific Considerations

Explores additional elements required when applicable, including biobanking, genetic testing, and commercial use disclosures.

2.3 Readability, Health Literacy, and Document Design

Practical guidance on writing at appropriate reading levels, using plain language, and designing documents that facilitate comprehension.

3.1 Preparing for the Consent Discussion

How to prepare yourself, the environment, and materials before initiating the consent conversation.

3.2 Conducting the Discussion: A Step-by-Step Approach

A structured approach to walking through the consent document, emphasizing dialogue over monologue.

3.3 Handling Questions, Concerns, and Therapeutic Misconception

Strategies for answering difficult questions, addressing concerns about risks, and identifying and correcting therapeutic misconception.

3.4 Cultural considerations and language access

Working with interpreters, using short-form consent documents, and adapting approaches for diverse cultural backgrounds.

4.1 Assessing Comprehension: Beyond 'Do You Understand?'

Validated methods for assessing comprehension including teach-back, open-ended questions, and formal assessment tools.

4.2 Decision-Making Capacity: Assessment and Considerations

Understanding decision-making capacity, when and how to assess it, and distinguishing capacity from competency.

4.3 Voluntariness, Coercion, and Undue Influence

Recognizing the spectrum from acceptable persuasion to prohibited coercion, and ensuring truly voluntary participation.

5.1 Parental permission: Requirements and waivers

Understanding when one versus two parents must provide permission, and circumstances permitting waiver of parental permission.

5.2 The Assent Process: Engaging Children and Adolescents

Age-appropriate communication with minors, developing assent documents, and determining when assent is required versus waived.

5.3 Adolescent participants and transition to adult consent

Special considerations for adolescents, mature minor doctrine, and managing participants who age into adulthood during a study.

6.1 Consent for cognitively impaired adults

Working with legally authorized representatives, maintaining participant involvement, and managing fluctuating capacity.

6.2 Emergency research and exception from informed consent

Understanding EFIC requirements under 21 CFR 50.24, community consultation, and public disclosure obligations.

6.3 Other Vulnerable Populations: Prisoners, Employees, and Students

Additional protections for prisoners (Subpart C), employees, students, and economically disadvantaged individuals.

7.1 Documenting the Consent Process

What to document, where to document it, and common documentation deficiencies identified during inspections.

7.2 Protocol Amendments and the Reconsent Decision

Determining when protocol changes require reconsent and how to manage the reconsent process efficiently.

7.3 Ongoing Communication: New Information and Safety Updates

Communicating new safety information, IND safety reports, and changes to the benefit-risk balance during the trial.

8.1 Common Consent Failures and FDA Findings

Analysis of frequent consent-related inspection findings, warning letter citations, and patterns of failure.

8.2 Case Studies: Learning from Real-World Scenarios

Detailed fictionalized case studies based on actual consent failures, with analysis and discussion of what went wrong.

8.3 Prevention and Remediation Strategies

Quality assurance approaches, remediation when problems occur, and building a culture of ethical consent.

2.1 Required Elements: What Must Be Included

Comprehensive review of all elements required by 21 CFR 50.25(a) and ICH E6(R3), with rationale for each requirement.

2.2 Additional Elements and Study-Specific Considerations

Explores additional elements required when applicable, including biobanking, genetic testing, and commercial use disclosures.

2.3 Readability, Health Literacy, and Document Design

Practical guidance on writing at appropriate reading levels, using plain language, and designing documents that facilitate comprehension.

3.1 Preparing for the Consent Discussion

How to prepare yourself, the environment, and materials before initiating the consent conversation.

3.2 Conducting the Discussion: A Step-by-Step Approach

A structured approach to walking through the consent document, emphasizing dialogue over monologue.

3.3 Handling Questions, Concerns, and Therapeutic Misconception

Strategies for answering difficult questions, addressing concerns about risks, and identifying and correcting therapeutic misconception.

3.4 Cultural considerations and language access

Working with interpreters, using short-form consent documents, and adapting approaches for diverse cultural backgrounds.

4.1 Assessing Comprehension: Beyond 'Do You Understand?'

Validated methods for assessing comprehension including teach-back, open-ended questions, and formal assessment tools.

4.2 Decision-Making Capacity: Assessment and Considerations

Understanding decision-making capacity, when and how to assess it, and distinguishing capacity from competency.

4.3 Voluntariness, Coercion, and Undue Influence

Recognizing the spectrum from acceptable persuasion to prohibited coercion, and ensuring truly voluntary participation.

5.1 Parental permission: Requirements and waivers

Understanding when one versus two parents must provide permission, and circumstances permitting waiver of parental permission.

5.2 The Assent Process: Engaging Children and Adolescents

Age-appropriate communication with minors, developing assent documents, and determining when assent is required versus waived.

5.3 Adolescent participants and transition to adult consent

Special considerations for adolescents, mature minor doctrine, and managing participants who age into adulthood during a study.

6.1 Consent for cognitively impaired adults

Working with legally authorized representatives, maintaining participant involvement, and managing fluctuating capacity.

6.2 Emergency research and exception from informed consent

Understanding EFIC requirements under 21 CFR 50.24, community consultation, and public disclosure obligations.

6.3 Other Vulnerable Populations: Prisoners, Employees, and Students

Additional protections for prisoners (Subpart C), employees, students, and economically disadvantaged individuals.

7.1 Documenting the Consent Process

What to document, where to document it, and common documentation deficiencies identified during inspections.

7.2 Protocol Amendments and the Reconsent Decision

Determining when protocol changes require reconsent and how to manage the reconsent process efficiently.

7.3 Ongoing Communication: New Information and Safety Updates

Communicating new safety information, IND safety reports, and changes to the benefit-risk balance during the trial.

8.1 Common Consent Failures and FDA Findings

Analysis of frequent consent-related inspection findings, warning letter citations, and patterns of failure.

8.2 Case Studies: Learning from Real-World Scenarios

Detailed fictionalized case studies based on actual consent failures, with analysis and discussion of what went wrong.

8.3 Prevention and Remediation Strategies

Quality assurance approaches, remediation when problems occur, and building a culture of ethical consent.